Strona główna・Stock List・ADMA Biologics Inc

ADMA Biologics Inc

Closed

SectorHealthcare

8.26 -1.08

Buy Sell

Overview

Share price change

24h

Current

Min

8.17

Max

8.39

Key metrics
By Trading Economics
Income	-4.1M 45M
Sales	-25M 114M
P/E Sector Avg	12.868 62.58
EPS	0.17
Profit margin	39.59
Employees	640
EBITDA	-4.2M 61M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+123.06% upside

Dividends
By Acuity
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	-367M 2B
Previous open	9.34
Previous close	8.26

News Sentiment

By Acuity

91%

320 / 340 Ranking in Healthcare

ADMA Biologics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 lip 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22 lip 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21 lip 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20 lip 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Price Target

By TipRanks

123.06% upside

12 Months Forecast

Average 18.67 USD 123.06%

High 21 USD

Low 17 USD

Based on 3 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to ADMA Biologics Inc - Dist in the past 3 months.

Sentiment

By Acuity

320 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.